SynCardia Honored with Two Gold Stevie® Awards
at the 2012 American Business AwardsSM
Total Artificial Heart Manufacturer Recognized as "Company of the Year – Health Products & Services"
and "Most Innovative Company of the Year – up to 100 Employees"
TUCSON, Ariz. – June 20, 2012 – On June 18, SynCardia Systems, Inc., manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, was honored with two Gold Stevie® Awards at the 10th Annual American Business Awards. SynCardia won "Company of the Year – Health Products and Services" and "Most Innovative Company of the Year – up to 100 Employees."
"We are honored to be recognized as an industry leader by the nation's premier business awards program," said Michael Garippa, SynCardia Chairman/CEO/President. "With donor hearts in short supply, the SynCardia temporary Total Artificial Heart powered by the Freedom® portable driver is rapidly becoming the new standard of care for end-stage biventricular (both ventricles) heart failure."
On April 24, SynCardia completed the minimum enrollment required by its FDA-approved Investigational Device Exemption (IDE) clinical study of the Freedom portable driver, the world's first wearable power supply for the Total Artificial Heart. Weighing 13.5 pounds, the Freedom portable driver is designed to allow stable Total Artificial Heart patients who meet discharge criteria to leave the hospital and resume their lives at home while they wait for a matching donor heart. The Freedom driver, which is also CE approved for use in Europe, has supported more than 85 patients worldwide, accounting for more than 30 patient years of support.
Nicknamed the Stevies for the Greek word for "crowned," the trophies were presented to honorees during a gala banquet on Monday, June 18 at the Marriott Marquis Hotel in New York. More than 500 nominees and their guests attended. The presentations were broadcast live by the Business TalkRadio Network. More than 3,000 nominations from organizations of all sizes and in virtually every industry were submitted this year for consideration.
CAUTION – The Freedom® portable driver is an investigational device, limited by United States law to investigational use.
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,250 implants of the Total Artificial Heart, accounting for more than 335 patient years of life on the device.
Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at 93 SynCardia Certified Centers worldwide with 35 others in the process of certification.
The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.
Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"
In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition.